Grape King Bio Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Grape King Bio.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Personal Products	17.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Feb 27

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Nov 20

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Grape King Bio no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

TWSE:1707 - Estimaciones futuras de los analistas y datos financieros pasados (TWD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	11,205	1,470	1,590	2,313	N/A
6/30/2024	10,857	1,421	1,000	1,632	N/A
3/31/2024	10,763	1,431	1,954	2,550	N/A
12/31/2023	10,635	1,453	1,918	2,519	N/A
9/30/2023	10,559	1,456	2,019	2,571	N/A
6/30/2023	10,501	1,454	2,182	2,776	N/A
3/31/2023	10,558	1,501	2,410	2,977	N/A
12/31/2022	10,391	1,457	2,488	2,990	N/A
9/30/2022	10,186	1,426	2,287	2,664	N/A
6/30/2022	10,097	1,363	2,725	3,066	N/A
3/31/2022	9,879	1,304	2,218	2,539	N/A
12/31/2021	9,798	1,300	2,264	2,542	N/A
9/30/2021	9,623	1,281	2,320	2,590	N/A
6/30/2021	9,387	1,283	2,305	2,558	N/A
3/31/2021	9,131	1,242	1,683	2,669	N/A
12/31/2020	9,168	1,272	1,493	2,719	N/A
9/30/2020	9,138	1,279	1,264	2,507	N/A
6/30/2020	9,082	1,280	1,121	2,444	N/A
3/31/2020	9,234	1,309	1,570	2,185	N/A
12/31/2019	9,239	1,309	1,516	2,171	N/A
9/30/2019	9,193	1,288	1,296	2,146	N/A
6/30/2019	9,303	1,323	1,631	2,685	N/A
3/31/2019	9,265	1,298	1,310	2,415	N/A
12/31/2018	9,183	1,295	1,296	2,417	N/A
9/30/2018	9,302	1,331	1,432	2,450	N/A
6/30/2018	9,325	1,322	N/A	2,245	N/A
3/31/2018	9,317	1,353	N/A	2,183	N/A
12/31/2017	9,388	1,352	N/A	2,496	N/A
9/30/2017	9,130	1,295	N/A	2,310	N/A
6/30/2017	9,183	1,298	N/A	2,409	N/A
3/31/2017	9,180	1,272	N/A	2,790	N/A
12/31/2016	9,185	1,297	N/A	2,803	N/A
9/30/2016	8,667	1,219	N/A	2,737	N/A
6/30/2016	8,099	1,148	N/A	1,475	N/A
3/31/2016	7,606	1,097	N/A	1,486	N/A
12/31/2015	7,248	1,052	N/A	1,307	N/A
9/30/2015	6,995	1,035	N/A	1,197	N/A
6/30/2015	6,777	1,019	N/A	2,567	N/A
3/31/2015	6,548	986	N/A	2,053	N/A
12/31/2014	6,283	942	N/A	1,922	N/A
9/30/2014	6,038	907	N/A	1,760	N/A
6/30/2014	5,913	867	N/A	1,140	N/A
3/31/2014	5,797	857	N/A	1,479	N/A
12/31/2013	5,639	836	N/A	1,576	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de 1707 es superior a la tasa de ahorro (1.1%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de 1707 crezcan más rápidamente que el mercado TW

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de 1707 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de 1707 crezcan más rápidamente que el mercado de TW.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de 1707 crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de 1707 se prevé que sea elevada dentro de 3 años.

Grape King Bio Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 12% to NT$170

Price target decreased to NT$195

Price target lowered to NT$206

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.81 (vs NT$2.48 in 3Q 2023)

Grape King Bio Ltd to Report Q3, 2024 Results on Nov 11, 2024

Now 21% overvalued

Second quarter 2024 earnings: EPS misses analyst expectations

Grape King Bio Ltd Announces Changes to Remuneration Committee

Grape King Bio Ltd to Report Q2, 2024 Results on Aug 12, 2024

Grape King Bio's (TWSE:1707) Dividend Will Be NT$6.90

Upcoming dividend of NT$6.90 per share

Grape King Bio (TWSE:1707) Will Pay A Dividend Of NT$6.90

Dividend of NT$6.90 announced

Grape King Bio Ltd Approves Changes to the Board

Grape King Bio Ltd Announces Dividend, Payable on July 18, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Grape King Bio Ltd to Report Q1, 2024 Results on May 13, 2024

Full year 2023 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 30, 2024

Price target decreased by 12% to NT$170

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Upcoming dividend of NT$6.90 per share at 3.9% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% undervalued after recent price drop

Now 21% undervalued

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of NT$6.10 per share

Grape King Bio Ltd Announces Cash Dividend

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS misses analyst expectations

Grape King Bio Ltd, Annual General Meeting, May 27, 2022

Grape King Bio Ltd Applies to FDA for A Phase II Clinical Trial Review in Humans for GKAC

Third quarter 2021 earnings released: EPS NT$2.04 (vs NT$2.23 in 3Q 2020)

Price target decreased to NT$195

Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$2.09 in 2Q 2020)

Upcoming dividend of NT$6.40 per share

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

First quarter 2021 earnings released: EPS NT$1.60 (vs NT$1.93 in 1Q 2020)

Grape King Bio (TPE:1707) Knows How To Allocate Capital

Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly

Grape King Bio's (TPE:1707) Anemic Earnings Might Be Worse Than You Think

Revenue beats expectations

How Much Did Grape King Bio's(TPE:1707) Shareholders Earn From Share Price Movements Over The Last Year?

Full year 2020 earnings released: EPS NT$9.34 (vs NT$9.63 in FY 2019)

Grape King Bio Ltd, Annual General Meeting, May 28, 2021

New 90-day high: NT$181

Grape King Bio Ltd announced that it expects to receive TWD 2.01467 billion in funding from Uni-President Enterprises Corp.

Grape King Bio (TPE:1707) Seems To Use Debt Quite Sensibly

Price target lowered to NT$206

Third quarter 2020 earnings released: EPS NT$2.23

Earnings beat expectations, revenue disappoints

New 90-day low: NT$167

New 90-day low: NT$176

New 90-day low - NT$178

New 90-day low - NT$184

First half earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento